Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: R>G> who wrote (3906)	9/6/1998 11:39:00 AM
From: Mike Ankley	Read Replies (2) \| Respond to of 5402

R>G> great find from the FDA regarding approval statistics. 20% approval rate for drugs tested on humans is definitely much more realistic (especially coming from FDA) than the grossly misleading statistic from forthright that only 1 out of 5000 drugs make it to market. (misleading because that stat is for brand new preclinical drugs - PHER-02 is 2nd generation, way beyond a brand new preclinical drug!) Also notice the various phase timeframes are much more realistic than the scare tactic numbers forthright threw out. While these FDA numbers are realistic for 'new' drugs, I'm not quite sure they are exactly applicable to PHER - being a 2nd generation drug. I'm still hunting down approval rates, time and cost statistics for 2nd generation drugs. If anyone else has these numbers, please post them. Cheers Mike